Hepatitis C Virus Infection
AVIRAtea PharmaceuticalsCatalyst overview
Research summary
This catalyst tracks a Phase 3 data readout for Bemnifosbuvir + Ruzasvir (RZR) in Hepatitis C Virus Infection. The expected timing is based on the latest available company guidance and may change.
C-BEYOND & C-FORWARD Ph3 Trials. 12/4/24- Met primary endpoints. 6/24/25- First patient dosed in Ph3 C-FORWARD trial. 11/12/25:- Ph3 enrollment on track. C-BEYOND topline mid-2026; C-FORWARD topline around end-2026. 12/22/25:- Completed C-BEYOND Ph3 enrollment. 05/13/26:- EASL 2026 posters May 29 on DDI and transport. 05/12/26:- HCV Ph3 C-BEYOND topline mid-2026; C-FORWARD enrollment completion mid-2026; topline around year-end 2026. 05/27/26:- EASL Ph1 DDI results: low interaction with omeprazole, digoxin, rosuvastatin. Ph3 topline still mid-2026. 06/25/26:- C-FORWARD enrollment completed. C-BEYOND topline mid-2026; C-FORWARD topline around year-end 2026. 07/28/26:- C-BEYOND Ph3 topline positive. C-FORWARD Ph3 topline expected Early 2027. 08/12/26:- C-BEYOND Phase 3 met primary and secondary endpoints. C-FORWARD topline will be reported Early Q1 2027; NDA submission will follow in Q2 2027.
Verification
Confirm timing and program details against the company announcement or filing.